1. Home
  2. AMWL vs IMUX Comparison

AMWL vs IMUX Comparison

Compare AMWL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Well Corporation

AMWL

American Well Corporation

HOLD

Current Price

$13.77

Market Cap

179.6M

Sector

Technology

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$7.40

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMWL
IMUX
Founded
2006
2016
Country
United States
United States
Employees
N/A
66
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.6M
155.8M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
AMWL
IMUX
Price
$13.77
$7.40
Analyst Decision
Hold
Strong Buy
Analyst Count
7
12
Target Price
$12.80
★ $43.09
AVG Volume (30 Days)
95.0K
★ 382.7K
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 57.06
38.00
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.66
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.71
$0.51
52 Week High
$14.56
$17.43

Technical Indicators

Market Signals
Indicator
AMWL
IMUX
Relative Strength Index (RSI) 58.53 36.21
Support Level $11.61 $6.35
Resistance Level $13.92 $8.60
Average True Range (ATR) 0.80 0.65
MACD 0.17 0.19
Stochastic Oscillator 76.72 46.67

Price Performance

Historical Comparison
AMWL
IMUX

About AMWL American Well Corporation

American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: